When cartilage loss and joint inflammation occur together

A diagnosis of Kellgren-Lawrence Grade III or IV knee osteoarthritis does not automatically mean surgery is the next step — but it does mean the joint is presenting two distinct problems that both need to be addressed.

At this stage of osteoarthritis, cartilage loss and synovial inflammation tend to coexist. The articular surfaces — the cartilage lining the ends of the bones — show focal or widespread damage. At the same time, the synovial lining of the joint becomes reactive: inflamed, thickened, and prone to producing excess fluid. These are structurally separate problems, affecting different tissues within the same joint.

Therapies that address only one component leave the other unresolved. A treatment aimed purely at calming inflammation does nothing for the cartilage surface loss driving mechanical pain; a scaffold placed at the bone end does not settle synovial reactivity. For patients presenting with confirmed dual pathology, a combined approach targeting each compartment separately has a coherent clinical basis.

That confirmation is a genuine prerequisite: not every Grade III or IV joint presents this way, and imaging — typically MRI — is needed to establish that both targets are present before either component of a combined protocol is considered appropriate.

How ChondroFiller and Arthrosamid work on different parts of the joint

The two injections in the CFI+ protocol work on different anatomical structures, which is precisely what makes delivering them together coherent.

ChondroFiller is a CE-marked, acellular Type I/III collagen scaffold — acid-extracted and imported from Germany — injected as a liquid directly onto the bone-end cartilage surfaces under ultrasound guidance. Once in position, it gels in situ, forming a three-dimensional matrix across the damaged area. This scaffold does not itself produce new cartilage; instead, it creates a chemotactic environment that draws the patient's own progenitor cells in from the surrounding tissue. Those cells populate the matrix and, over roughly 6–12 months, lay down cartilage-like tissue in its place. The mechanism is acellular matrix-induced chondrogenesis: regenerative in character, scaffold-led rather than cell-delivered.

Arthrosamid takes a structurally different route. The 2.5% polyacrylamide hydrogel (iPAAG), imported from Denmark, is injected into the synovial lining of the joint, where it integrates permanently into the tissue. It does not degrade and is not regenerative — its role is mechanical and palliative: cushioning the joint, reducing the mechanical irritation that drives inflammatory flares, and providing durable symptom relief. It acts on the synovium, not on the cartilage surface.

These targets sit in anatomically distinct compartments of the same joint: cartilage surfaces at the bone ends on one side, the synovial membrane lining the joint capsule on the other. Because neither product reaches the other's target tissue, co-delivery in a single outpatient appointment does not produce any interaction between them. One injection is regenerative and scaffold-based; the other is a long-lasting palliative hydrogel. Collapsing the two into a single 'filler' category would misrepresent what each is doing inside the joint.

What the evidence shows for each component — and what remains unproven

The evidence base for each component tells a notably uneven story — and being clear about that asymmetry is part of what an honest consultation conversation looks like.

Arthrosamid (iPAAG): sustained benefit at the individual-product level

Arthrosamid has the stronger formal evidence of the two. RCT extension data show that a single 6 mL intra-articular injection of 2.5% iPAAG produced mean WOMAC pain improvements of −13.1 points at three years (95% CI: −17.9 to −8.4; p<0.0001) and −16.2 points at five years (p<0.0001), with no device-related serious adverse events reported in either follow-up cohort. A 150-patient comparative study (KL Grade II–IV) found iPAAG outperformed corticosteroid at six months (p<0.001) and maintained stable WOMAC scores at twelve months, whereas hyaluronic acid and steroid returned to baseline — though the difference versus HA at twelve months did not reach statistical significance.

There is, however, a meaningful selection caveat embedded in the real-world data. A 314-knee cohort found that higher KL grade was independently associated with a greater likelihood of requiring total knee replacement (p<0.001), and that the best MCID outcomes occurred in older, non-diabetic patients with lower KL grades. Grade III/IV patients are the cohort for whom the combination is most often considered — yet they are also those in whom iPAAG alone shows diminishing returns. Diabetes further reduces the probability of reaching a meaningful response across all three PROMs in that dataset.

ChondroFiller: strong focal-defect data, more limited Grade III/IV evidence

ChondroFiller's published literature is weighted towards focal cartilage defects. In knee cases, outcome anchors include approximately 30-point IKDC score improvement and MOCART scores of 70–87 at follow-up. Equivalent evidence specifically for diffuse Grade III/IV osteoarthritis, where the damage is more widespread rather than focal, is limited.

The combination: rationale without a trial

No direct clinical trial data exists for the CFI+ protocol as a combined intervention. Each product carries its own regulatory approval — ChondroFiller as a CE-marked Class III device, Arthrosamid as approved for symptomatic adult knee OA — and the combined pathway is in active clinical use. What the evidence cannot currently confirm is whether delivering both together slows OA progression or delays the need for knee replacement. That gap does not negate the anatomical rationale set out by the treating clinicians, but it is a factor patients should raise explicitly at consultation.

Which patients are suitable candidates

Qualifying for the CFI+ protocol is a clinical decision that requires both components to be independently justified — a Grade III/IV diagnosis alone is not sufficient.

Assessment begins with MRI and clinical review, which together confirm whether both pathological targets are genuinely present. On the structural side, imaging needs to show addressable cartilage surface involvement at the bone ends. For the synovial component, active inflammation typically declares itself clinically — pain at rest, persistent effusion, or recurring flares — and MRI can further corroborate synovial thickening or marked joint fluid. If only one pathology is confirmed, the combination is not the appropriate pathway; each product is added only where there is a specific reason to add it.

The patient factors flagged in the real-world evidence — higher KL grade correlating with greater TKR risk, and diabetes reducing the likelihood of a meaningful response to the Arthrosamid component — feed directly into this gatekeeping. Some patients presenting at Grade III/IV will, after assessment, be counselled towards joint replacement rather than injection therapy; others may qualify for one product but not both.

That makes the selection process clinician-led by design. Two patients arriving with the same radiograph can reach entirely different conclusions at consultation, depending on their clinical picture, inflammatory pattern, metabolic history, and functional goals. The imaging confirms the anatomy; the consultation weighs the full context.

What the CFI+ appointment involves

Once imaging has confirmed both targets, treatment takes place in a single outpatient clinic visit. Both injections are placed under ultrasound guidance — ChondroFiller onto the bone-end cartilage surfaces, Arthrosamid separately into the synovial lining — in the same appointment, without theatre admission or anaesthetic. The two placements are anatomically distinct; neither product is mixed or co-injected, and the sequence is determined by the treating clinician on the day.

The published package price — quoted from £5,500 at London Cartilage Clinic, with the same guide figure cited independently by MSK Doctors — covers consultation, ultrasound guidance, both products, and a six-week follow-up appointment. A clinical reference document notes £6,000 as the specified guide cost for the advanced KL Grade III/IV dual-injection tier, confirmed at assessment. What falls outside the package is worth budgeting for separately: MRI scanning (typically required before the appointment to confirm candidacy), physiotherapy, and travel costs are all additional.

The two components also work to different timescales, and setting those expectations clearly is part of the pre-treatment conversation. Arthrosamid integrates into the synovial lining and its cushioning, anti-inflammatory effect may be felt within weeks to months of injection. ChondroFiller operates on a slower biological clock: the acellular collagen scaffold recruits the body's own repair cells to produce cartilage-like matrix gradually over 6 to 12 months. Modest symptomatic change at the six-week follow-up does not, therefore, indicate that the regenerative component has not taken effect — the repair process is still under way.

What the combined protocol costs and how to take the next step

For context, the combined guide costs compare favourably with purchasing each product separately. ChondroFiller alone is priced at £3,000 for one box, rising to £5,500 for two and £8,000 for three; standalone Arthrosamid follows the same pricing structure. The combined pathway, in other words, is not simply the sum of two independent treatments invoiced side by side.

For a small group of patients with more extensive or refractory disease, a further tier exists. The Tri-Active package — ChondroFiller, Arthrosamid, and autologous mesenchymal stem cells sourced from bone marrow, fat, or ear cartilage — is documented at £11,000. Suitability for that option is determined at consultation and is not offered routinely.

On funding, the position is straightforward. Neither product is NHS-funded, and standard private medical insurance does not cover either. Patients should confirm their individual policy wording with their insurer before committing to treatment, as exclusions vary by policy.

The CFI+ protocol occupies a specific place on the treatment pathway: a non-surgical option for a defined pattern of Grade III/IV disease — dual pathology confirmed on imaging — not a general response to advanced knee OA. Patients who reach this stage typically have exhausted conventional symptom management and are looking for a credible option before joint replacement becomes the only remaining conversation. Establishing whether that description fits an individual case, given their imaging, clinical picture, and functional goals, is what an assessment at London Cartilage Clinic is structured to determine.

1. [1] Sustained symptom relief and safety over five years following a single intra-articular injection of 2.5% polyacrylamide hydrogel in patients with knee OA. (2025). https://doi.org/10.55563/clinexprheumatol/bsper8 https://doi.org/10.55563/clinexprheumatol/bsper8